Edition:
United States

Profile: Verastem Inc (VSTM.OQ)

VSTM.OQ on NASDAQ Stock Exchange Global Market

5.15USD
20 Sep 2017
Change (% chg)

-- (--)
Prev Close
$5.15
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
222,926
52-wk High
$5.71
52-wk Low
$1.07

Verastem, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company's advanced product candidates are VS 6063, VS 4718 and VS 5584. The Company's programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. FAK is a non-receptor tyrosine kinase encoded by the PTK-2 gene that is involved in cellular adhesion and, in cancer, metastatic capability. The Company's VS-6063 (defactinib) and VS 4718 are orally available small molecule compounds designed to inhibit FAK signaling. The Company's VS-5584 is an orally available small molecule that inhibits both mTORC1/2 and PI3K signaling. The Company is engaged in running clinical trials in cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

Company Address

Verastem Inc

117 Kendrick St Ste 500
NEEDHAM   MA   02494-2730
P: +1781.2924200
F: +1914.9499618

Company Web Links